What it's for (Indications)
- Ephedrine, available in both injectable and oral formulations, is a sympathomimetic amine primarily indicated for the treatment of clinically significant hypotension occurring in the setting of anesthesia.
- The injectable form is acutely employed to raise blood pressure, often in the intraoperative period, through its vasoconstrictive effects.
- Historically, oral ephedrine was used for various conditions including bronchial asthma, allergic disorders, and as a nasal decongestant due to its bronchodilatory and vasoconstrictive properties.
- However, its use for asthma and allergic conditions has largely been superseded by more selective and safer agents.
- Its application in modern clinical practice for these indications is limited, with the injectable form predominantly used in critical care and surgical settings for hemodynamic support.
- The decision to use ephedrine must always weigh its potent vasoconstrictive and cardiac stimulatory effects against potential risks, ensuring appropriate patient selection and monitoring.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of ephedrine varies significantly based on the route of administration, the patient's clinical condition, and the specific indication. For the treatment of hypotension during anesthesia, ephedrine injection is typically administered intravenously (IV) in bolus doses of 5 to 10 mg, which may be repeated as needed based on the patient's hemodynamic response, up to a maximum single dose of 50 mg. The total daily dose generally should not exceed 150 mg. Alternatively, it can be given intramuscularly (IM) or subcutaneously (SC) at doses ranging from 25 to 50 mg, with subsequent doses adjusted according to patient response. For oral administration, historically used for conditions such as asthma, typical adult doses ranged from 25 mg to 50 mg every 3 to 4 hours. Pediatric doses were significantly lower and carefully calculated based on weight. Due to its narrow therapeutic index and significant potential for adverse effects, particularly cardiovascular and central nervous system stimulation, careful titration and vigilant monitoring of vital signs are imperative with ephedrine administration, irrespective of the route. |
Safety & Warnings
Common Side Effects
- As a potent sympathomimetic, ephedrine can elicit a wide range of side effects primarily related to its adrenergic stimulation.
- Common adverse effects include tachycardia, palpitations, hypertension, anxiety, nervousness, insomnia, headache, dizziness, tremors, nausea, vomiting, and sweating.
- These effects are generally dose-dependent.
- More serious but less common adverse events can involve cardiac arrhythmias, myocardial ischemia or infarction, cerebrovascular events (e.
- g.
- , stroke, cerebral hemorrhage), angina pectoris, and severe hypertension, especially in susceptible individuals or with overdose.
- Central nervous system effects can extend to psychosis, paranoia, hallucinations, or seizures.
- Urinary retention, particularly in men with prostatic hyperplasia, is another recognized side effect.
- Patients may also experience dyspnea or feelings of apprehension.
- Due to its systemic effects, vigilant monitoring for these adverse reactions is crucial during and after ephedrine administration, especially in critically ill or elderly patients.
Serious Warnings
- Black Box Warning: ### SERIOUS WARNINGS: SEVERE CARDIOVASCULAR AND CENTRAL NERVOUS SYSTEM ADVERSE EVENTS Ephedrine carries a significant risk for serious and potentially life-threatening cardiovascular and central nervous system (CNS) adverse reactions, particularly when used inappropriately, in high doses, or in susceptible individuals. These adverse events include, but are not limited to, acute hypertension, tachycardia, palpitations, myocardial infarction, cerebral hemorrhage, stroke, arrhythmias (including ventricular fibrillation), and sudden cardiac death. CNS effects such as seizures, psychosis, hallucinations, and severe anxiety have also been reported. The potential for these severe reactions is heightened in individuals with pre-existing cardiovascular disease, hypertension, diabetes, hyperthyroidism, or psychiatric disorders. Concomitant use with other sympathomimetic agents, caffeine, or other stimulants can exacerbate these risks. Due to its potent pharmacological activity, ephedrine should only be administered under strict medical supervision and careful hemodynamic monitoring, especially in acute care settings. The therapeutic benefits must be carefully weighed against the substantial risk of severe morbidity and mortality associated with its use.
- Ephedrine requires extreme caution in patients with pre-existing cardiovascular conditions such as hypertension, coronary artery disease, angina pectoris, or cardiac arrhythmias, as it can significantly exacerbate these states leading to myocardial ischemia, infarction, or potentially fatal arrhythmias.
- It should be used judiciously in patients with hyperthyroidism, diabetes mellitus, or pheochromocytoma due to heightened sensitivity to sympathomimetic effects.
- Caution is also warranted in patients with prostatic hypertrophy, as it can induce acute urinary retention.
- Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOIs is strictly contraindicated due to the risk of hypertensive crisis.
- Similarly, co-administration with other sympathomimetic agents can lead to additive cardiovascular effects.
- Patients receiving general anesthesia with halogenated hydrocarbons may be sensitized to the arrhythmogenic effects of ephedrine.
- Pregnant women should use ephedrine only if the potential benefit outweighs the potential risk to the fetus, as it can cross the placental barrier and affect fetal heart rate.
- Breastfeeding mothers should also exercise caution due to potential excretion into breast milk.
- Careful patient selection, thorough medical history, and continuous hemodynamic monitoring are essential to mitigate risks.
How it Works (Mechanism of Action)
Ephedrine exerts its pharmacological effects through a dual mechanism involving both direct and indirect actions on alpha (α) and beta (β) adrenergic receptors throughout the body. Directly, ephedrine acts as an agonist on both α- and β-adrenergic receptors. Its direct α-agonist activity primarily leads to vasoconstriction, increasing systemic vascular resistance and, consequently, elevating blood pressure. Its direct β-agonist activity stimulates the heart, increasing heart rate (positive chronotropy) and contractility (positive inotropy), which further contributes to increased cardiac output and blood pressure. Simultaneously, and perhaps more significantly for its overall effect, ephedrine acts indirectly by stimulating the release of endogenous norepinephrine from sympathetic nerve terminals. This released norepinephrine then acts on α- and β-adrenergic receptors, amplifying the sympathomimetic response. This indirect action is a key component of its pressor effect. Furthermore, ephedrine also possesses central nervous system (CNS) stimulant properties, leading to effects such as wakefulness, reduced fatigue, and potential anxiety or restlessness, by acting on adrenergic receptors within the brain.